127 related articles for article (PubMed ID: 31689915)
1. The Histone Methyltransferase DOT1L Is a Functional Component of Estrogen Receptor Alpha Signaling in Ovarian Cancer Cells.
Salvati A; Gigantino V; Nassa G; Giurato G; Alexandrova E; Rizzo F; Tarallo R; Weisz A
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31689915
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial targeting of menin and the histone methyltransferase DOT1L as a novel therapeutic strategy for treatment of chemotherapy-resistant ovarian cancer.
Alexandrova E; Lamberti J; Memoli D; Quercia C; Melone V; Rizzo F; Tarallo R; Giurato G; Nassa G; Weisz A
Cancer Cell Int; 2022 Nov; 22(1):336. PubMed ID: 36333801
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
Zhang X; Liu D; Li M; Cao C; Wan D; Xi B; Li W; Tan J; Wang J; Wu Z; Ma D; Gao Q
J Hematol Oncol; 2017 Jan; 10(1):29. PubMed ID: 28114995
[TBL] [Abstract][Full Text] [Related]
5. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
Kari V; Raul SK; Henck JM; Kitz J; Kramer F; Kosinsky RL; Übelmesser N; Mansour WY; Eggert J; Spitzner M; Najafova Z; Bastians H; Grade M; Gaedcke J; Wegwitz F; Johnsen SA
Clin Epigenetics; 2019 Jan; 11(1):4. PubMed ID: 30616689
[TBL] [Abstract][Full Text] [Related]
6. Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis.
Chava S; Bugide S; Edwards YJK; Gupta R
Oncogenesis; 2021 Jul; 10(7):48. PubMed ID: 34253709
[TBL] [Abstract][Full Text] [Related]
7. Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer.
Wang X; Wang H; Xu B; Jiang D; Huang S; Yu H; Wu Z; Wu Q
Am J Transl Res; 2019; 11(2):1145-1153. PubMed ID: 30899413
[TBL] [Abstract][Full Text] [Related]
8. Histone Methyltransferase DOT1L as a Promising Epigenetic Target for Treatment of Solid Tumors.
Alexandrova E; Salvati A; Pecoraro G; Lamberti J; Melone V; Sellitto A; Rizzo F; Giurato G; Tarallo R; Nassa G; Weisz A
Front Genet; 2022; 13():864612. PubMed ID: 35495127
[TBL] [Abstract][Full Text] [Related]
9. Feedback control of the CXCR7/CXCL11 chemokine axis by estrogen receptor α in ovarian cancer.
Benhadjeba S; Edjekouane L; Sauvé K; Carmona E; Tremblay A
Mol Oncol; 2018 Oct; 12(10):1689-1705. PubMed ID: 30051594
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer.
Tokuda E; Seino Y; Arakawa A; Saito M; Kasumi F; Hayashi S; Yamaguchi Y
Breast Cancer Res Treat; 2012 Jun; 133(2):427-36. PubMed ID: 21909982
[TBL] [Abstract][Full Text] [Related]
11. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
12. Histone methyltransferase Dot1L is a coactivator for thyroid hormone receptor during
Wen L; Fu L; Shi YB
FASEB J; 2017 Nov; 31(11):4821-4831. PubMed ID: 28739643
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor α-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer.
Shen Y; Cao J; Liang Z; Lin Q; Wang J; Yang X; Zhang R; Zong J; Du X; Peng Y; Zhang J; Shi J
Cell Commun Signal; 2019 May; 17(1):50. PubMed ID: 31122254
[TBL] [Abstract][Full Text] [Related]
14. Sesterterpene MHO7 suppresses breast cancer cells as a novel estrogen receptor degrader.
Zhao Y; Zhao C; Lu J; Wu J; Li C; Hu Z; Tian W; Yang L; Xiang J; Zhou H; Deng Z; Huang J; Hong K
Pharmacol Res; 2019 Aug; 146():104294. PubMed ID: 31175940
[TBL] [Abstract][Full Text] [Related]
15. The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers.
Légaré S; Cavallone L; Mamo A; Chabot C; Sirois I; Magliocco A; Klimowicz A; Tonin PN; Buchanan M; Keilty D; Hassan S; Laperrière D; Mader S; Aleynikova O; Basik M
Cancer Res; 2015 Oct; 75(20):4351-63. PubMed ID: 26297734
[TBL] [Abstract][Full Text] [Related]
16. The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity.
Peterson TJ; Karmakar S; Pace MC; Gao T; Smith CL
Mol Cell Biol; 2007 Sep; 27(17):5933-48. PubMed ID: 17591692
[TBL] [Abstract][Full Text] [Related]
17. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.
Albanito L; Madeo A; Lappano R; Vivacqua A; Rago V; Carpino A; Oprea TI; Prossnitz ER; Musti AM; Andò S; Maggiolini M
Cancer Res; 2007 Feb; 67(4):1859-66. PubMed ID: 17308128
[TBL] [Abstract][Full Text] [Related]
18. Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer.
Yu L; Liang Y; Cao X; Wang X; Gao H; Lin SY; Schiff R; Wang XS; Li K
Oncogene; 2017 May; 36(20):2910-2918. PubMed ID: 27893709
[TBL] [Abstract][Full Text] [Related]
19. p33(ING1b) stimulates the transcriptional activity of the estrogen receptor alpha via its activation function (AF) 2 domain.
Toyama T; Iwase H; Yamashita H; Hara Y; Sugiura H; Zhang Z; Fukai I; Miura Y; Riabowol K; Fujii Y
J Steroid Biochem Mol Biol; 2003 Oct; 87(1):57-63. PubMed ID: 14630091
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
